# US 2006/0084129 A1 · Novel ways of assessing metabolic processes

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2006/0084129 A1
- Document ID: US20060084129A1
- Status: Published application
- Kind: A1
- Application number: 11/296,829
- Filed: 2005-12-06
- Published: 2006-04-20
- Earliest claimed: 2002-03-11
- Assignees: Lipomics Technologies, Inc.
- Inventors: Steven Watkins
- Web page: https://patentgrep.com/patent/US20060084129A1

## CPC

- G01N 33/92: involving lipids, e.g. cholesterol {, lipoproteins, or their receptors (steroid hormones G01N33/743)}
- A61K 31/00: Medicinal preparations containing organic active ingredients
- A61K 31/4415: Pyridoxine, i.e. Vitamin B6 (pyridoxal phosphate A61K31/675)
- A61K 31/455: Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
- A61K 31/51: Thiamines, e.g. vitamin B1
- A61K 31/519: ortho- or peri-condensed with heterocyclic rings
- A61K 31/7076: containing purines, e.g. adenosine, adenylic acid
- A61K 38/27: Growth hormone [GH], i.e. somatotropin
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 25/00: Drugs for disorders of the nervous system
- C12N 9/1003: {transferring one-carbon groups (2.1)}
- C12Y 201/01017: Phosphatidylethanolamine N-methyltransferase (2.1.1.17)
- G01N 33/5758: {involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites}
- G01N 2800/52: Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Y: ENZYMES

## Abstract

The present invention provides methods for assessing contribution of one or more pathways to the biosynthesis of a metabolite, e.g., a lipid using the levels of the product made and the metabolite precursors for each pathway.

## Claims

### Claim 1

A method for determining the contribution of a pathway to the biosynthesis of a lipid class comprising
determining the level of a marker composition in a precursor,
determining the level of the marker composition in a lipid class,
wherein the precursor is transformed to the lipid class via a pathway, and wherein the level of the marker composition in the precursor relative to the level of the marker composition in the lipid class is indicative of the contribution of the pathway to the biosynthesis of the lipid class.

### Claim 2

A method of determining the contribution of a first pathway and a second pathway to the biosynthesis of a lipid class comprising
determining P1, wherein P1 is the level of a marker composition in a first precursor of a lipid class,
wherein the first precursor is transformed to the lipid class via the first pathway,
determining P2, wherein P2 is the level of the marker composition in a second precursor
of the lipid class,
wherein the second precursor is transformed to the lipid class via the second pathway,
determining TL, wherein TL is the level of the marker composition in the lipid class,
wherein the contribution of the first pathway is represented by (TL−P2)/(P1−P2) and the contribution of the second pathway is represented by (TL−P1)/(P2−P1).

### Claim 3 (depends on 2)

The method of claim 2, wherein the marker composition is a SN-1 position fatty acid.

### Claim 4 (depends on 2)

The method of claim 2, wherein the marker composition is a fatty acid selected from the group consisting of 16:0, 18:0, 18:1, 18:2, 20:4, and 22:6.

### Claim 5 (depends on 2)

The method of claim 2, wherein the level of the marker composition is represented by the level of 18:0 or 16:0.

### Claim 6 (depends on 2)

The method of claim 2, wherein the level of the marker composition is represented by the ratio of at least two fatty acids at SN-1 position.

### Claim 7 (depends on 2)

The method of claim 2, wherein the level of the marker composition is represented by the ratio of 18:0 to 16:0.

### Claim 8 (depends on 2)

The method of claim 2, wherein the level of the marker composition is represented by the ratio of any two of 18:0, 16:0, 18:1, 18:2, 20:4, and 22:6.

### Claim 9 (depends on 2)

The method of claim 2, wherein the level of the marker composition is represented by the ratio of any three of 18:0, 16:0, 18:1, 18:2, 20:4, and 22:6.

### Claim 10 (depends on 2)

The method of claim 2, wherein the lipid class is phosphatidylcholine.

### Claim 11 (depends on 2)

The method of claim 2, wherein the lipid class is phosphatidylethanolamine, cholesterol ester, phosphatidylserine, phosphatidylinositol, cardiolipin, triacylglyceride, diacylglyceride, phosphatidic acid, free fatty acid, sphingomyelin, phosphatidylglycerol, or lysophosphalipids.

### Claim 12 (depends on 2)

The method of claim 2, wherein the lipid class is phosphatidylcholine, the first pathway is phosphatidylethanolamine-N-methyltransferase (PEMT) pathway, and the second pathway is CDP-choline pathway.

### Claim 13 (depends on 2)

The method of claim 2, wherein the lipid class is phosphatidylcholine, the first pathway is phosphatidylethanolamine-N-methyltransferase (PEMT) pathway and the first precursor is phosphatidylethanolamine.

### Claim 14 (depends on 2)

The method of claim 2, wherein the lipid class is phosphatidylcholine, the second pathway is CDP-choline pathway and the second precursor is selected from the group consisting of diacylglyceride, phosphatidic acid, and triacylglyceride.

### Claim 15 (depends on 2)

The method of claim 2, wherein the lipid class is phosphatidylethanolamine, the first pathway is phosphatidylserine decarboxylase pathway and the second pathway is CDP-ethanolamine pathway.

### Claim 16 (depends on 2)

The method of claim 2, wherein the lipid class is phosphatidylethanolamine, the first pathway is phosphatidylserine decarboxylase pathway and the first precursor is phosphatidylserine.

### Claim 17 (depends on 2)

The method of claim 2, wherein the lipid class is in plasma.

### Claim 18 (depends on 2)

The method of claim 2, wherein the lipid class is in liver.

### Claim 19 (depends on 2)

The method of claim 2, wherein the lipid class is in brain, heart, mammary gland, or intestine.

### Claim 20

A method of determining the level of a marker composition of phosphatidylcholine in liver comprising determining the level of the marker composition of phosphatidylcholine in plasma.